Peptide vs Polypeptide vs Protein

Chemically there is no discontinuity between a peptide and a protein. Both are chains of amino acids joined by amide bonds, and the words mark a rough gradient in length and behaviour rather than a change in kind. Common usage calls a chain of two to roughly ten residues an oligopeptide, anything up to about fifty a peptide, and longer chains polypeptides or proteins, with the extra implication that a protein folds into a defined tertiary structure and often assembles with other chains, whereas a short peptide is frequently disordered in solution.

The vagueness ends at the regulatory line. In United States law, following the Biologics Price Competition and Innovation Act and the transition that took effect in March 2020, a chain of forty or fewer amino acids is a peptide and is regulated as a drug, while anything longer is a protein and therefore a biologic. That single count decides which application a sponsor files, whether a copy can be approved as a generic under the abbreviated pathway or must be a biosimilar, and which exclusivity clock applies. Insulin, at 51 residues across two chains, moved from drug to biologic on that basis. Semaglutide, at 31 residues, stays on the peptide side of the line and is handled as a drug.

That is why the distinction is worth caring about beyond vocabulary. It determines whether a follow-on version can be compounded, whether it can be approved as a generic, and what evidence a competitor has to produce.

The misuse to watch is marketing that calls something a peptide to borrow the lighter regulatory connotation, or a protein to sound more like a biologic. The word does not confer a status; the residue count and the resulting pathway do, and a compound with no approval at all sits outside both categories regardless of what it is called.